Stockreport

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

Benitec Biopharma Inc.  (BNTC) 
US:NASDAQ Investor Relations: benitec.com/for-investors/investor-faqs
PDF -The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers wer [Read more]